Answers are grounded in this paper and cite their sources.
BAFF and APRIL are clinically validated targets in multiple autoantibody-associated diseases. Their inhibition has shown promise in IgA nephropathy (IgAN), lupus nephritis (LN), and primary membranous nephropathy (pMN), with the potential to exert a disease-modifying effect. Povetacicept (ALPN-303) is an Fc fusion protein of a variant TACI domain engineered for more potent dual BAFF/APRIL inhibition than wild-type TACI or anti-BAFF or anti-APRIL antibodies. Povetacicept administration has been associated with on-target reductions in circulating immunoglobulins, including galactose-deficient IgA1 (Gd-IgA1), and antibody-secreting cells in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Tumlin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: